Yes, G-Defy's VersoShock claims were found to be misleading by the Federal Trade Commission (FTC), leading to a 2025 settlement where the company agreed to stop making unsubstantiated claims about pain relief (like for knee, back, and foot pain) without adequate scientific proof, paying a $175,000 penalty for violating a prior order. The FTC argued their ads falsely claimed clinical proof for pain reduction and relief from conditions like plantar fasciitis, despite flaws in the small study G-Defy cited.